The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Conditions:   Langerhans Cell Histiocytosis;   Erdheim-Chester Disease;   LCH;   ECD Intervention:   Drug: HLX208 Sponsor:   Shanghai Henlius Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials